Pharmacist Training on the Administration of Long-Acting Injectable Antipsychotics (LAIA)

July 22, 2019 - September 28, 2019

Florida A&M University
College of Pharmacy & Pharmaceutical Sciences
1415 S. Martin Luther King, Jr. Blvd
Tallahassee, Florida 32307

Sponsored by the:
College of Pharmacy
Office of Continuing Pharmacy Education
Tallahassee, Florida 32307
(850) 599-3240 or (850) 599-3301
Online Modules  
July 22 – September 27, 2019

Live Training  
Saturday, September 28, 2019  
9:00 a.m. – 1:30 p.m.  
Pharmacist Training on the Administration of Long-Acting Injectable Antipsychotics (LAIAs)

GENERAL INFORMATION

Fee: $500.00

Ways to Register and Payment Method: 
Online Registration: http://www.cvent.com/d/7yqp4k/4W □ Debit Card □ Credit Card

Target Audience: Pharmacists

Financial Support: This activity is supported by an educational grant from Janssen Scientific Affairs, LLC and Alkermes, Inc.

Meeting Location: Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Pharmacy Building, 1415 S. Martin Luther King, Jr. Blvd., Tallahassee, Florida 32307; Corner of Martin Luther King, Jr. Blvd. and Pershing Street.

Meeting Rooms: 102 and 302

Note: As the temperature in meeting rooms vary, participants are encouraged to bring a sweater or jacket with them.

Parking: Parking will be available in the gated lot (Fredrick S. Humphries Science Research Lot) across from the New Pharmacy Building, 1415 S. Martin Luther King, Jr. Boulevard, Tallahassee, FL and in surrounding areas on September 28, 2019.

Americans with Disabilities Act: If a participant requires a reasonable accommodation according to the Americans with Disabilities Amendment Act (ADAA), please contact the Office of Continuing Pharmacy Education at (850) 599-3240 at least ten working days before the start of the event.

Grievance Policy: All grievances regarding the Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health should be communicated in writing to the director of the Office of Pharmacy Continuing Education. Grievances will be reviewed and
acknowledged by mail within 30 days after receipt. Unsatisfactory responses to grievances should be communicated in writing to the dean of FAMU COPPS.

**Cancellation Policy:** All cancellation requests must be made in writing. Requests may be made by email to leola.cleveland@famu.edu. All request for refunds made before August 16, 2019, will be honored and charged a $25 administrative fee. No refunds will be given for cancellations made after August 16, 2019. If a participant needs to communicate with Mrs. Cleveland, contact her at (850) 599-3240.

Once registered, participants will be contacted regarding access to the four (4) hours of online home study modules to be completed before the 4-hour live hands-on training. The hands-on training will be on Saturday, September 28, 2019, in Tallahassee, FL. In the event a participant cannot attend the live training on August 10th, participants need to attend a future live training to complete course requirements, for which dates are currently to be determined. This training is the pilot program, and completion during this cycle is strongly suggested.

**Attendance and Evaluation Forms:** Participants must complete the Online modules, attend the Live Training, and complete Speaker and Program evaluations to receive credits. As confirmation of attendance, participants will be required to complete a continuing education attendance form. Each participant will receive an evaluation link to complete the on-line evaluation form.

**Use of Trade Names:** The trade names of the drugs and delivery systems in this module are for the purpose of product identification only. This activity does not intend to imply endorsement for any commercial products discussed.

**Continuing Education Credits:** Continuing Education Credits will be posted on the CE Broker and CPE Monitor upon completion of all 8 hours ~ four (4) hours Online Modules and four (4) hours Live Training.

**Accreditations:** The Florida Department of Health Board of Pharmacy approves Florida A&M University College of Pharmacy and Pharmaceutical Sciences as a provider of Continuing Pharmacy Education (CPE).

Florida A&M University College of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of Continuing Pharmacy Education.

ACPE is working in partnership with the National Association of Boards of Pharmacy (NABP) to authenticate and store data for completed CPE units received by pharmacists and pharmacy technicians from ACPE-accredited providers. Pharmacists and pharmacy technicians may obtain their NABP e-Profile ID, the Unique Identification number required when registering for a CPE activity from an ACPE-accredited provider by going to [www.nabp.net](http://www.nabp.net).
TARGET AUDIENCE

Pharmacists: This program is approved for the following:

Home Study credit hours for pharmacists. Offering four contact hours (4 CEUs) of General CE Broker Course Tracking Number: 20-730270.

AND

Live credit hours for pharmacists. Offering four contact hours (4 CEUs) of General CE Broker Course Tracking Number: 20-730274.

PROGRAM GOAL

Knowledge and application-based continuing education activities are guided by the ACPE Standards and Quality Assurance Procedures for ACPE-accredited providers of Continuing Pharmacy Education offering Certificate Programs in Florida. The goal of this program is to provide an opportunity for program participants to acquire knowledge and apply the necessary skills for administering Long-Acting Antipsychotic Injections (LAIAs).

PROGRAM OUTCOMES

Through participation in the program, participants will be able to do the following:

1. Summarize the clinical implications and benefits from a pharmacist-physician collaboration for caregivers and patients utilizing antipsychotic long-acting injectables.
2. Develop strategies to identify and manage personal biases about mental health disorders.
3. Recognize and understand the impact psychosocial factors have on patients suffering from mental health disorders.
4. Describe the signs, symptoms, diagnostic criteria, and basic pathophysiology of schizophrenia, schizoaffective, and bipolar disorder.
5. Describe the evidence and rationale for the use of long-acting antipsychotics to prevent relapse in schizophrenia, schizoaffective, and bipolar disorder.
6. Outline the dosages, mechanisms of action, pharmacokinetics, adverse events, significant drug interactions, and warnings/precautions for long-acting injectable antipsychotics used in the treatment of schizophrenia, schizoaffective, and bipolar disorder.
7. Landmark and identify intramuscular and subcutaneous injection sites.
8. Identify equipment for intramuscular and subcutaneous injections.
9. Demonstrate the appropriate technique for intramuscular and subcutaneous administration of long-acting antipsychotic injections.

PROGRAM REQUIREMENTS

Participant Responsibilities: In order to satisfy the 8-hour CE requirements of the Pharmacist Administration of Long-Acting Antipsychotic Injections, participants must complete both the online modules and live training. Activities include module pre-tests, recorded lectures, post-tests, and speaker and program evaluation.
PROGRAM STRUCTURE
Through engagement in the 4-hour online comprehensive series and the 4-hour live hands-on training, participants will be able to earn the required 8 hours of CE in order to administer LAIAs. Participants will receive access to handouts, bibliographies, and recorded lectures to be completed before the live 4-hour training. The program is structured for the online modules to be completed at the participant's pace but should be completed before September 28, 2019. Participants will be assessed. Use of Trade Names: The trade names of the drugs and delivery systems in this module are for the purpose of product identification only. This activity does not intend to imply endorsement for any commercial products discussed.

Online Comprehensive Series
The participant must be provided access to four hours of online home study to be completed. For each online module, participants will be provided access to presentation documents and recorded lectures. This aspect of the program emphasizes the psychosocial and treatment aspect of those disorders which can be treated by LAIAs (Schizophrenia, Schizoaffective, and Bipolar disorder), with emphasis on the pharmacist’s role in treating this population. As part of the online component, participants will take a pre-test to determine their base knowledge on the topics, and following the modules, they will take a post-test as their assessment. The participants will also evaluate each presentation and faculty associated with the program.

Practical Live Hands-on Training
Upon completion of the online modules, participants will be able to attend the live hands-on training for learning how to administer the specific LAIAs. As part of the live training, participants will be assessed on their demonstration of the various injection techniques. Upon completion of the hands-on training, participants will assess the faculty during this module, and ultimately assess the program as a whole.

About Our Faculty
Dr. Rajiv Tandon ~ Module 1
Rajiv Tandon, MD, is the Professor and Chairman of Psychiatry at the WMED Homer Stryker College of Medicine in Kalamazoo, Michigan. Dr. Tandon has authored more than 400 scientific publications and given over 1200 national and international scientific presentations. He has received several awards for research and teaching in schizophrenia, including the 2010 and 2016 SIRS (International Schizophrenia Research Society) Senior Researcher of the Year awards for the most cited paper in schizophrenia between 2008-10 (2010) and the most downloaded paper in schizophrenia between 2014-2016 (2016). Dr. Tandon has received the Exemplary Psychiatrist Award from the National Alliance for Mental Illness on three occasions: in 2009, 2012, and 2015. He was a member of the DSM-5 workgroup on schizophrenia and related psychotic disorders and is a member of the World Psychiatry Association Pharmacopsychiatry Section. He is the immediate Past-President of the Florida chapter of the National Alliance for Mental Illness and the
immediate Past-President of the Florida Psychiatric Society. His primary areas of clinical and research interest are the neuropharmacology of schizophrenia, differences between typical and atypical antipsychotic agents, dimensions of schizophrenic psychopathology, neuroendocrine and polysomnographic abnormalities in schizophrenia, and the evidence-based treatment of schizophrenia and other major mental disorders.

**Dr. Claudia Vicencio ~ Module 2**
Claudia Vicencio, Ph.D., LCSW, LMFT, is the Clinical Supervisor for Outpatient Behavioral Health at Memorial Regional Hospital in Hollywood, Florida. Along with Alberto Augsten, PharmD, BCPP, DABAT, she also created and managed multiple innovative programs to treat opioid and other substance use disorders—including the award-winning Mothers in Recovery Program. Dr. Vicencio is passionate about designing programs that address the social determinants of health by connecting hospital services to community resources. She is an engaging and dynamic speaker and educator. Her research and clinical practice expertise include the treatment of drug addiction in pregnancy, social work-pharmacy collaboration, evidence-based models for behavioral health practice, and mediating the impact of childhood adversity on adults with behavioral health conditions. Dr. Vicencio obtained her Ph.D. in Social Work, focusing her doctoral research on the impact of childhood adversity on adults’ attitudes toward seeking professional mental health treatment. Her previous work includes managed care, inpatient psychiatry the work with adolescents and their families. Dr. Vicencio is dedicated to improving access to effective behavioral health treatment for vulnerable populations and aspires to live in a world where childhood adversity is eradicated through person-centered care for adults with psychiatric disorders.

**Dr. Leonard Rappa ~ Module 3**
Dr. Rappa is a tenured professor that began his academic career with Florida A&M University, College of Pharmacy and Pharmaceutical Sciences in December of 1998. Dr. Rappa received his Doctor of Pharmacy degree (with honors) in 1995 from Nova Southeastern University, and subsequently became their first Psychopharmacology specialty resident from 1995-1996. After completion of his residency, he moved to Sarasota, Florida to become Sarasota Memorial’s Psychiatric Pharmacy Specialist. In 1997, Dr. Rappa became Board Certified as a Psychiatric Pharmacist and maintained that certification yearly. In December of 1998, he returned to South Florida to assume a full-time faculty position with Florida A&M University’s Miami Campus, College of Pharmacy. At that time, he established a practice site at Memorial Regional Hospital in Hollywood, Florida, teaching the sixth-year doctoral students on their Psychiatry Pharmacy clinical clerkship rotation. At Memorial, he integrated himself and the students well into the non-teaching environment, making the milieu very open to a pseudo-teaching atmosphere. Over the next 18 years of practice, he trained hundreds of students, residents, and other pharmacists in psychopharmacology. With his guidance, the internal clinical pharmacy services evolved, and at the time he departed, there were several full-time psychiatric pharmacists and a specialized Post-graduate Year II (PGY-2) pharmacy resident. At the beginning of 2017, he established a new clinical practice in Fort Lauderdale at Broward Health Imperial Point and has made great inroads in establishing clinical pharmacy services to the Behavioral Health patients and staff.
Dr. Shari Allen ~ Module 4
Dr. Allen earned her PharmD from Florida A&M University College of Pharmacy and Pharmaceutical Sciences. After graduation, she completed an ASHP accredited PGY-1 (General Practice) and PGY-2 (Psychiatry) residency at the Buffalo Psychiatric Center in Buffalo, NY. She is now an Associate Professor of Pharmacy Practice at Philadelphia College of Osteopathic Medicine (PCOM) - School of Pharmacy, where she has been for eight years. Dr. Allen teaches in a Therapeutics Course, Pharmacy Practice Lab, and a Psychiatry Elective at PCOM-SOP. She also maintains a pharmacy practice site at the Atlanta VA Medical Center in Decatur, Georgia. Dr. Allen volunteers her time with organizations such as the College of Psychiatric and Neurologic Pharmacists (CPNP), ASHP, Georgia Pharmacy Association (GPhA), and the National Alliance on Mental Illness (NAMI) when she is not teaching at PCOM-SOP.

Ms. Hannah Phillips ~ Module 5
Ms. Phillips received her BSN and MSN degrees in the Psychiatric-Mental Health Nurse Practitioner Program (PMHNP) from the University of Florida. She is a member of the National Alliance on Mental Illness and the American Psychiatric Nurses Association. Ms. Phillips currently serves as an adjunct clinical facility preceptor for PMHNP students from the University of Florida. Ms. Phillips’ passions include but are not limited to: cats, Florida history, photography, urban exploration, and LAIA.

Ms. Ana Alonso ~ Module 5
Ms. Alonso has worked as a Psychiatric Registered Nurse, and she has 22 years of experience in behavioral health with Aspire Health Partners, formerly known as Lakeside Behavioral Healthcare in Orlando, Florida. During her tenure with Aspire Health Partners, she oversaw the administration of LAIAs which had approximately 600 patients on the injections, for which she averaged 350 injections per month. Given her expertise, she has seen firsthand the benefits of LAIAs over oral medication, not only from the patient’s perspective but also the practitioner’s perspective. Ms. Alonso is very excited about training pharmacists and looks forward to instructing on the proper techniques for intramuscular and subcutaneous injections.
<table>
<thead>
<tr>
<th>MODULE 1</th>
<th>Topic, Faculty, and Activity</th>
<th>Objectives</th>
</tr>
</thead>
</table>
| **Presentation:** The Physician’s Perspective on the Role of Pharmacists in Administering Long-Acting Injectable Antipsychotics  
UAN# 0011-0000-19-020-H01-P, Knowledge-Based  
0.5 Contact Hours  
Initial Release: 7/19/2019  
Expiration: 7/19/2022  
**Faculty:** Rajiv Tandon, MD, DLFAPA, Professor and Chair, Department of Psychiatry, Homer Stryker Western Michigan University College of Medicine, Kalamazoo, Michigan  
**Activities:**  
1. Pre-test  
2. Module Review  
3. Post-test | 1. Define the statute language allowing for pharmacists to administer antipsychotic long-acting injectable.  
2. Describe and differentiate the psychiatric patient population utilizing antipsychotic long-acting injectables.  
3. Summarize the clinical implications and benefits from a pharmacist-physician collaboration for caregivers and patients utilizing antipsychotic long-acting injectables. |
| MODULE 2 | Topic, Faculty, and Activity | Objectives |
| **Presentation:** Psychosocial Considerations for Long-Acting Injectable Antipsychotic Providers  
UAN# 0011-0000-19-018-H01-P, Knowledge-Based  
0.5 Contact Hours  
Initial Release: 7/19/2019  
Expiration: 7/19/2022  
**Faculty:** Claudia Vicencio, Ph.D., LCSW, LMFT, Clinical Supervisor, Outpatient Behavioral Health, Memorial Regional Hospital, Hollywood, Florida  
**Activities:**  
1. Pre-test  
2. Module Review  
3. Post-test | 1. Define stigma and discuss the prevalence of stigma in healthcare professionals.  
2. Describe the impact of stigma on individuals’ access to care and the effectiveness of treatment.  
3. Develop strategies to identify and manage personal biases about mental health disorders.  
4. Recognize and understand the impact psychosocial factors have on patients suffering from mental health disorders. |
## MODULE 3

**Presentation:** Managing Schizophrenia and Schizoaffective Disorder with Long-Acting Injectable Antipsychotics  
**UAN# 0011-0000-19-019-H01-P, Knowledge-Based**  
2 Contact Hours  
Initial Release: 7/19/2019  
Expiration: 7/19/2022

**Faculty:** Leonard Rappa, Pharm.D., BCCP, CPh, Professor, Division of Pharmacy Practice, FAMU College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Davie Instructional Site, Davie, Florida

**Activities:**
1. Pre-test  
2. Module Review  
3. Post-test

1. Describe the signs, symptoms, diagnostic criteria, and basic pathophysiology of schizophrenia and schizoaffective disorder.  
2. Describe the evidence and rationale for the use of long-acting antipsychotics to prevent relapse in schizophrenia and schizoaffective disorder.  
3. Outline the dosages, mechanisms of action, pharmacokinetics, adverse events, significant drug interactions, and warnings/precautions for long-acting injectable antipsychotics used in the treatment of schizophrenia and schizoaffective disorder.  
4. Explain appropriate safety monitoring for LAIAs used in the treatment of schizophrenia and schizoaffective disorder.  
5. Identify important counseling information to be discussed with patients being administered LAIAs for the treatment of schizophrenia and schizoaffective disorder.  
6. Recognize the patient and family psychosocial perspective and contributions to patient acceptance and recognition of treatment needs.

## MODULE 4

**Presentation:** Bipolar Disorder and Long-Acting Injectable Antipsychotics  
**UAN# 0011-0000-19-021-H01-P, Knowledge-Based**  
1 Contact Hour  
Initial Release: 7/19/2019  
Expiration: 7/19/2022

**Faculty:** Shari Allen, Pharm.D., BCPP, Assistant Professor of Pharmacy Practice, Philadelphia College of Osteopathic Medicine – School of Pharmacy, Suwanee, Georgia

**Activities:**
1. Pre-test  
2. Module Review  
3. Post-test

1. Describe the signs, symptoms, diagnostic criteria, and basic pathophysiology of bipolar disorder.  
2. Describe the evidence and rationale for the use of long-acting antipsychotics to prevent relapse in bipolar disorder.  
3. Outline the dosages, mechanisms of action, pharmacokinetics, adverse events, significant drug interactions, and warnings/precautions for long-acting injectable antipsychotics used in the treatment of a bipolar disorder.  
4. Explain appropriate safety monitoring for LAIAs used in the treatment of a bipolar disorder.  
5. Identify important counseling information to be discussed with patients being administered LAIAs for the treatment of a bipolar disorder.  
6. Recognize the patient and family psychosocial perspective and contributions to patient acceptance and recognition of treatment needs.

## MODULE 5: LIVE TRAINING SATURDAY SEPTEMBER 28, 2019

**Presentation:** Long-Acting Injectable Antipsychotic Hands-on Training: Basics and Beyond  
**Faculty:** Hannah Phillips, MSN, PMHNP-BC, Psychiatric Nurse Practitioner, Big Bear Behavioral Health and Grace Medical Home, Orlando, Florida  
Ana Alonso, BSN, Registered Nurse, Doctor of Nursing Student, University of South Alabama, Orlando, Florida

**Moderator:** Soheyla Mahdavian, Pharm.D., BCGP, Associate Professor,

1. Analyze the benefits of utilizing long-acting injectable antipsychotic medications.  
2. Illustrate the advantages of LAIAs over oral formulations in first-episode psychosis.  
3. Use key factors to consider when selecting a second-generation LAIAs for an individual patient.  
4. Compare barriers to using SGA LAIA therapy and potential strategies to overcoming these barriers in clinical practice.  
5. Examine how to obtain informed consent and the 5 Rights of Medical Administration.  
6. Differentiate and employ intramuscular and subcutaneous injection sites.  
7. Examine equipment for intramuscular and subcutaneous injections.  
8. Demonstrate the appropriate technique for intramuscular and subcutaneous administration of long-acting antipsychotic injections.  
9. Distinguish physical space requirements for administering a long-acting antipsychotic injection.  
10. Discuss Occupational Safety and Health Administration regulations for the prevention
Division of Pharmacy Practice, Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Tallahassee, Florida

UAN# 0011-0000-19-022-L01-P, Application-Based
4 Contact Hours
Initial Release: 7/19/2019
Expiration: 7/19/2022

Activities:
1. Lecture
2. Injection demonstration and assessment
3. Speaker and Program evaluation

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Outline principles and procedures for injection storage and handling.</td>
</tr>
<tr>
<td>12</td>
<td>Describe the signs and symptoms of generalized and local adverse reactions to long acting antipsychotic injections and procedures that pharmacists should follow to manage various adverse reactions.</td>
</tr>
<tr>
<td>13</td>
<td>Educate patients about potential adverse reactions following the receipt of a long acting antipsychotic injection and how to manage them.</td>
</tr>
<tr>
<td>14</td>
<td>Describe appropriate documentation and follow-up after injection administration.</td>
</tr>
</tbody>
</table>